Status:
COMPLETED
POST-CABGDM: Empagliflozin in Perioperative CABG
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Diabetes Mellitus, Type 2
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surg...
Detailed Description
Random Prospective Study non-blinded with 144 diabetics patients designated to myocardial revascularization with cardiopulmonary bypass . 72 patients will be randomly set to usual treatment provided b...
Eligibility Criteria
Inclusion
- Age \> 18
- Type 2 diabetes mellitus
- Multivessel CAD documented by coronary angiography with formal indication for CRM.
Exclusion
- eGFR \<30mL / min / 1.73m2 or dialysis therapy;
- Inability to sign the informed consent form;
- Contraindication to CABG on pump;
- Need for urgent or emergency CABG;
- Terminal or disabling illness with reduced life expectancy;
- Pregnancy in progress.
Key Trial Info
Start Date :
September 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2024
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT04523064
Start Date
September 22 2020
End Date
January 30 2024
Last Update
June 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Sao Paulo Medical School - The Heart Institute
São Paulo, São Paulo, Brazil, 05403010